Idenix Pharmaceuticals Reports First Quarter 2008 Financi...( CAMBRIDGE Mass. April 29 /- Ideni...),Health

CAMBRIDGE, Mass., April 29 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral and other infectious diseases, today reported unaudited financial results for the first quarter ended March 31, 2008. At March 31, 2008, Idenix's cash, cash equivalents and marketable securities totaled approximately $99.0 million.

2008 Year-to-Date Business Highlights

-- Idenix reported positive data from an ongoing phase I/II study of

IDX899, a non-nucleoside reverse transcriptase inhibitor (NNRTI) being

developed for the treatment of HIV-1. In the first dosing cohort of

this study, eight HIV-1 infected treatment-naive patients receiving 800

mg of IDX899 once-daily achieved a median reduction in plasma virus

levels of approximately 2.0 log10, or 99 percent, after seven days of

treatment. The 400 mg cohort of this study is now complete and dosing

has been initiated in the 200 mg cohort. To date, no serious adverse

events have been reported and no patients have discontinued from the

study. Data from this clinical trial have been submitted for

presentation at scientific meetings this summer.

-- The company continued to make progress with its hepatitis C discovery

and development programs, having presented data from preclinical

studies of its lead nucleotide prodrug candidate, IDX184, and potential

clinical candidates from its protease inhibitor program at the annual

meeting of the European Association for the Study of the Liver (EASL)

last week. (Please see Idenix press releas
'/>"/>